Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NeuroPace (NPCE) EBITDA (2020 - 2026)

NeuroPace has reported EBITDA over the past 7 years, most recently at -$5.6 million for Q1 2026.

  • For Q1 2026, EBITDA fell 8.18% year-over-year to -$5.6 million; the TTM value through Mar 2026 reached -$16.8 million, up 18.48%, while the annual FY2025 figure was -$16.3 million, 24.61% up from the prior year.
  • EBITDA for Q1 2026 was -$5.6 million at NeuroPace, down from -$1.8 million in the prior quarter.
  • Over five years, EBITDA peaked at -$1.8 million in Q4 2025 and troughed at -$13.2 million in Q2 2022.
  • A 5-year average of -$7.5 million and a median of -$7.3 million in 2023 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: crashed 54.52% in 2022 and later skyrocketed 51.63% in 2025.
  • Year by year, EBITDA stood at -$10.9 million in 2022, then soared by 43.22% to -$6.2 million in 2023, then soared by 41.08% to -$3.7 million in 2024, then skyrocketed by 51.63% to -$1.8 million in 2025, then tumbled by 215.11% to -$5.6 million in 2026.
  • Business Quant data shows EBITDA for NPCE at -$5.6 million in Q1 2026, -$1.8 million in Q4 2025, and -$2.6 million in Q3 2025.